Japan· JP-1149032F1132

エトドラク

A etodolac product containing エトドラク, registered in Japan by 沢井製薬, on the national reimbursement list. The same ATC class is registered in 7 of our 19 countries.

On Japan’s NHI price listATC M01AB08

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedエトドラクATCM01AB08REGISTER NO.JP-1149032F1132PACKS LISTED0CHECKEDSeptember 25, 2026

Where it is registered

Etodolac is registered in 7 of 19 countries.

Countries holding a registration under ATC M01AB08 (etodolac), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 4 of them publish a price we can compare per daily dose

Etodolac · ATC M01AB08

7 / 19 countries

  • Denmark
  • Finlandprice
  • Franceprice
  • Japan
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of etodolac costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), the median price runs from $0.43 in France to $0.80 in Switzerland — a ×1.9 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Etodolac · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

  • CH Switzerland$0.80
  • FR France$0.43
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

MHLW / PMDA (Japan)
Active substance
エトドラク
Manufacturer
沢井製薬
Country
Japan (JP)
ATC code
M01AB08
ATC class
Etodolac
Defined daily dose
0.4 g, O
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

368 interactions on record for etodolac.

Graded by severity as the source publishes them — 57 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Etodolac · interactions on record

368 records

  • 57 severe
  • 140 moderate
  • 5 minor
  • 85 info

Most severe, free to view

  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • DalteparinB01AB04severe
  • EnoxaparinB01AB05severe

81 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f913ef43-c272-40d7-b03a-a6a20d3498c5
GET /v1/drugs/f913ef43-c272-40d7-b03a-a6a20d3498c5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "100mg1錠",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "1149032F1132",
  "category": "内用薬",
  "price_yen": 6.3,
  "generic_name": "エトドラク",
  "product_name_jp": null,
  "therapeutic_class": "1149",
  "transitional_expiry": null
}

See everything about etodolac.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.